Skip to search formSkip to main contentSkip to account menu

TLR 7/8 Agonist MEDI9197

Known as: Toll-like Receptor 7/8 Agonist MEDI9197, TLR7/TLR8 Dual Agonist MEDI9197, MEDI 9197 
A toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, TLR7… 
National Institutes of Health

Related topics

Related topics

1 relation
3M 052

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors
Recent successes in immuno-oncology have focussed primarily on the T-cell synapse, targeting co-activatory /inhibitory pathways… 
2016
2016
Abstract 1475: Local immune activation resulting in tumor growth inhibition with MEDI9197 - an intratumorally administered TLR7/8 agonist
MEDI9197 (formerly 3M-052) is a sustained-release imidazoquinoline toll like receptor (TLR) TLR7/8 agonist designed with a lipid… 
2016
2016
A phase 1, first-time-in-human study of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with a solid tumor cancer.
TPS3095Background: Toll-like receptors (TLRs) are proteins in the innate immune system that, once bound to their ligands… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)